drugset
drugset / Trial / NCT06412068

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

NCT06412068 ↗

Phase 2 Unknown 32 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with R-CHOP regimen as first-line treatment for primary mediastinal large B-cell Lymphoma (PMBCL)

Timeline

Start
2024-06-01
Primary completion
2026-06-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Liposome doxorubicin Unknown 40 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

primary mediastinal large B-cell lymphoma